A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy
Understand AAV workflows through detailed lab and bioinformatic processes!
Adeno-associated virus (AAV) vectors have become an ideal vehicle for in vivo gene therapy due to their efficiency and safety in humans. However, there are many challenges to overcome during the AAV production process for rapid drug development.
Led by Andrea O'Hara, Ph.D., this workshop will help you understand the AAV workflow by covering AAV lab and bioinformatics analysis processes. Starting with upstream development, we review the gene synthesis, AAV plasmid preparation, and sequencing options available for AAV production and validation. We then discuss downstream analysis of the final packaged product to confirm purity, clonality, and fidelity.
Presenters and Roundtable Experts
- Andrea O’Hara, Ph.D., Strategic Technical Specialist, Azenta
- Elizabeth Louie, Ph.D., Supervisor, Technical Applications, Azenta
- Xiangying (Candy) Mao, Ph.D., Team Lead, Bioinformatics, Azenta
- Ming Yang, Ph.D., Business Process Manager, Azenta
- Liz Tseng, Ph.D., Associate Director, PacBio
- How to optimize AAV plasmid preparation
- Best practices to address unstable sequencing
- Solutions for storing and indexing AAV products
- Selection of purity and fidelity assays
- Bioinformatics tools for interpreting complex data
- GLP sequencing confirmation solutions
To learn more, fill out the form to watch the on-demand workshop today!